磁性ナノ粒子市場 : 2030年までの予測

Report Description

Magnetic Nanoparticles Market Research Report Forecast to 2030

Market Overview
Magnetic nanoparticles define as the use of tiny particles that possess magnetic properties are typically ranging from 1 to 500 nanometres in size. Magnetic Nanoparticles is receptor immobilized magnetic nanoparticles bind specifically to bacteria and viruses. It is a core technology that can separate and concentrate target pathogens through magnetism. After directly synthesizing magnetic nanoparticles, self-coating is performed to prevent aggregation and then, various functional groups possessed are fixed to realize a concentrating effect. These nanoparticles are often composed of magnetic materials such as iron, cobalt, or nickel, or their alloys. They exhibit unique characteristics such as magnetic behavior at the nanoscale, which can be manipulated and controlled for various applications including wastewater treatment, electronics, healthcare sector, biomedical, energy and other application. Magnetic nanoparticles have a wide range of uses in different fields due to their special properties. Most notably, magnetic nanoparticles are frequently employed in cancer treatment methods like magnetofection, photothermal therapy, photodynamic therapy, targeted drug delivery, and magnetic hyperthermia.
However, the fluctuations in the prices of magnetic nanoparticles materials and toxicity and biocompatibility of magnetic nanoparticles materials will likely restrain market growth. On the other hand, to rise in demand for magnetic nanoparticles from wastewater industry will create growth opportunities for the US and China Magnetic Nanoparticles market.
Market Segmentation
The functional group of magnetic particles has been majorly classified into -COOH, -NH2, -SiO2, -Tosyl , and -Streptavidin.
The size range of magnetic particles has been majorly classified into 100, 200, 300, and 500 nm. The size of magnetic particles can greatly impact their magnetic behavior, surface area, stability, and interactions with other molecules or systems.
Regional Analysis
The US and China Magnetic Nanoparticles market is expected to be driven by increasing expansion of biomedical and healthcare sector in US and China. The Increase usage of magnetic nanoparticles technology in process of pretreatment kits are driving the US Magnetic Nanoparticles market.
Major Players
Qiagen N. V., Bioneer Corporation, T2 Biosystems Inc., Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Creative Biogene, Baker Coulters Inc. (Danaher Corporation), MagBio Genomics Inc., DaAn Gene Co., Ltd, and MagGenome Technologies Pvt. Ltd among others are the major companies in the Magnetic Nanoparticles Market.

TABLE OF CONTENTS

1 MARKET INTRODUCTION ………………………………………………………………………….. 13
1.1 DEFINITION……………………………………………………………………………………………………………… 13
1.2 SCOPE OF THE STUDY ………………………………………………………………………………………………. 13
1.3 RESEARCH OBJECTIVE ……………………………………………………………………………………………… 14
1.4 MARKET STRUCTURE ………………………………………………………………………………………………… 14
1.5 LIST OF ASSUMPTIONS ……………………………………………………………………………………………… 15
2 MARKET DYNAMICS ………………………………………………………………………………….. 16
2.1 OVERVIEW ………………………………………………………………………………………………………………. 16
2.2 DRIVERS …………………………………………………………………………………………………………………. 17
2.2.1 EXPANSION OF BIOMEDICAL AND HEALTHCARE SECTOR IN US ………………………….. 17
2.2.2 EXPANSION OF BIOMEDICAL AND HEALTHCARE SECTOR IN CHINA …………………….. 18
2.2.3 INCREASE USAGE OF MAGNETIC NANOPARTICLES TECHNOLOGY IN PRETREATMENT KITS ………………………………………………………………………………… 20
2.3 RESTRAINTS ……………………………………………………………………………………………………………. 22
2.3.1 FLUCTUATIONS IN THE PRICES OF MAGNETIC NANOPARTICLES MATERIALS IN CHINA ………………………………………………………………………………………………… 22
2.3.2 FLUCTUATIONS IN THE PRICES OF MAGNETIC NANOPARTICLES MATERIALS IN US ……………………………………………………………………………………………………… 24
2.3.3 TOXICITY AND BIOCOMPATIBILITY OF MAGNETIC NANOPARTICLES MATERIALS …… 26
2.4 OPPORTUNITIES ………………………………………………………………………………………………………. 28
2.4.1 INCREASING USE OF MAGNETIC NANOPARTICLES FOR WATER TREATMENT …………. 28
2.5 TRENDS ………………………………………………………………………………………………………………….. 29
2.5.1 CORE TECHNOLOGY OF MAGNETIC NANOPARTICLES THAT CAN SEPARATE AND CONCENTRATE TARGET PATHOGENS THROUGH MAGNETISM …………………….. 29
2.5.2 NANODIAGNOSTIC TECHNOLOGIES FOR SEPSIS USING MAGNETIC NANOPARTICLES (MNPS) …………………………………………………………………………… 31
3 QUALITATIVE ANALYSIS ON FUNCTIONAL GROUP AND SIZE FOR MAGNETIC NANOPARTICLES …………………………………………………………….. 35
3.1 BY FUNCTIONAL GROUP ……………………………………………………………………………………………. 35
3.2 BY SIZE …………………………………………………………………………………………………………………… 37
3.3 OVERVIEW OF MAGNETIC BEAD-BASED METHOD EMPLOYED IN BIO-DIAGNOSTICS ……………… 39
4 COMPETITIVE LANDSCAPE ……………………………………………………………………….. 41
4.1 INTRODUCTION ………………………………………………………………………………………………………… 41
4.2 COMPETITIVE ANALYSIS……………………………………………………………………………………………. 42
4.3 MARKET SHARE ANALYSIS ………………………………………………………………………………………… 43
4.4 MAJOR GROWTH STRATEGY IN THE MAGNETIC NANOPARTICES MARKET (BIO-DIAGNOSTIC END USERS) …………………………………………………………………………………….. 43
4.5 COMPETITIVE BENCHMARKING ………………………………………………………………………………….. 44
4.6 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN MAGNETIC NANOPARTICLES MARKET ………………………………………………………………………………………….. 46
4.7 KEY DEVELOPMENTS & GROWTH STRATEGIES ………………………………………………………………. 47
4.7.1 PRODUCT LAUNCH/ PRODUCT DEVELOPMENT ……………………………………………….. 47
4.7.2 PARTNERSHIP/COLLABORATION …………………………………………………………………. 48
4.8 MAJOR PLAYER FINANCIAL* ………………………………………………………………………………………. 49
4.8.1 SALES, OPERATING INCOME, R&D EXPENDITURE 2022* ……………………………………. 49
5 COMPANY PROFILES ………………………………………………………………………………… 50
5.1 QIAGEN NV ……………………………………………………………………………………………………………… 50
5.1.1 COMPANY OVERVIEW ………………………………………………………………………………… 50
5.1.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 51
5.1.3 PRODUCTS OFFERED …………………………………………………………………………………. 52
5.1.4 KEY DEVELOPMENTS ………………………………………………………………………………… 53
5.1.5 SWOT ANALYSIS ………………………………………………………………………………………. 53
5.1.6 KEY STRATEGIES ………………………………………………………………………………………. 54
5.2 BIONEER CORPORATION ……………………………………………………………………………………………. 55
5.2.1 COMPANY OVERVIEW ………………………………………………………………………………… 55
5.2.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 55
5.2.3 PRODUCTS OFFERED …………………………………………………………………………………. 56
5.2.4 KEY DEVELOPMENTS ………………………………………………………………………………… 57
5.2.5 SWOT ANALYSIS ………………………………………………………………………………………. 57
5.2.6 KEY STRATEGIES ………………………………………………………………………………………. 58
5.3 T2 BIOSYSTEMS, INC. ……………………………………………………………………………………………….. 59
5.3.1 COMPANY OVERVIEW ………………………………………………………………………………… 59
5.3.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 59
5.3.3 PRODUCTS OFFERED …………………………………………………………………………………. 60
5.3.4 KEY DEVELOPMENTS ………………………………………………………………………………… 60
5.3.5 SWOT ANALYSIS ………………………………………………………………………………………. 61
5.3.6 KEY STRATEGIES ………………………………………………………………………………………. 61
5.4 THERMO FISHER SCIENTIFIC INC. ……………………………………………………………………………….. 62
5.4.1 COMPANY OVERVIEW ………………………………………………………………………………… 62
5.4.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 63
5.4.3 PRODUCTS OFFERED …………………………………………………………………………………. 64
5.4.4 KEY DEVELOPMENTS ………………………………………………………………………………… 65
5.4.5 SWOT ANALYSIS ………………………………………………………………………………………. 65
5.4.6 KEY STRATEGIES ………………………………………………………………………………………. 65
5.5 HOFFMANN-LA ROCHE LTD………………………………………………………………………………………… 66
5.5.1 FINANCIAL OVERVIEW ……………………………………………………………………………….. 67
5.5.2 PRODUCTS OFFERED …………………………………………………………………………………. 68
5.5.3 KEY DEVELOPMENTS ………………………………………………………………………………… 68
5.5.4 SWOT ANALYSIS ………………………………………………………………………………………. 69
5.5.5 KEY STRATEGIES ………………………………………………………………………………………. 69
5.6 CREATIVE BIOGENE ………………………………………………………………………………………………….. 70
5.6.1 COMPANY OVERVIEW ………………………………………………………………………………… 70
5.6.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 70
5.6.3 PRODUCTS OFFERED …………………………………………………………………………………. 71
5.6.4 KEY DEVELOPMENTS ………………………………………………………………………………… 71
5.6.5 SWOT ANALYSIS ………………………………………………………………………………………. 72
5.6.6 KEY STRATEGIES ………………………………………………………………………………………. 72
5.7 MAGGENOME TECHNOLOGIES PVT. LTD. ……………………………………………………………………… 73
5.7.1 COMPANY OVERVIEW ………………………………………………………………………………… 73
5.7.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 73
5.7.3 PRODUCTS OFFERED …………………………………………………………………………………. 74
5.7.4 KEY DEVELOPMENTS ………………………………………………………………………………… 75
5.7.5 SWOT ANALYSIS ………………………………………………………………………………………. 75
5.7.6 KEY STRATEGIES ………………………………………………………………………………………. 76
5.8 DAAN GENE CO., LTD. ……………………………………………………………………………………………….. 77
5.8.1 COMPANY OVERVIEW ………………………………………………………………………………… 77
5.8.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 77
5.8.3 PRODUCTS OFFERED …………………………………………………………………………………. 78
5.8.4 KEY DEVELOPMENTS ………………………………………………………………………………… 78
5.8.5 SWOT ANALYSIS ………………………………………………………………………………………. 79
5.8.6 KEY STRATEGIES ………………………………………………………………………………………. 79
5.9 MAGBIO GENOMICS INC. …………………………………………………………………………………………… 80
5.9.1 COMPANY OVERVIEW ………………………………………………………………………………… 80
5.9.2 FINANCIAL OVERVIEW ……………………………………………………………………………….. 80
5.9.3 PRODUCTS OFFERED …………………………………………………………………………………. 81
5.9.4 KEY DEVELOPMENTS ………………………………………………………………………………… 81
5.9.5 SWOT ANALYSIS ………………………………………………………………………………………. 82
5.9.6 KEY STRATEGIES ………………………………………………………………………………………. 82
5.10 BECKMAN COULTER INC. (DANAHER CORPORATION) …………………………………………………….. 83
5.10. COMPANY OVERVIEW ………………………………………………………………………………… 83
5.10. FINANCIAL OVERVIEW ……………………………………………………………………………….. 84
5.10. PRODUCTS OFFERED …………………………………………………………………………………. 85
5.10.4KEY DEVELOPMENTS ………………………………………………………………………………… 85
5.10.5SWOT ANALYSIS ………………………………………………………………………………………. 86
5.10.6KEY STRATEGIES………………………………………………………………………………………. 86
5.11 XI’AN TIANLONG SCIENCE AND TECHNOLOGY CO., LTD ………………………………………………….. 87
5.11.1COMPANY OVERVIEW ………………………………………………………………………………… 87
5.11.2FINANCIAL OVERVIEW ……………………………………………………………………………….. 87
5.11.3PRODUCTS OFFERED …………………………………………………………………………………. 88
5.11.4KEY DEVELOPMENTS ………………………………………………………………………………… 90
5.11.5SWOT ANALYSIS ………………………………………………………………………………………. 90
5.11.6KEY STRATEGIES………………………………………………………………………………………. 90
5.12 GUANGZHOU DONGSHENG BIOTECH CO., LTD ………………………………………………………………. 91
5.12.1COMPANY OVERVIEW ………………………………………………………………………………… 91
5.12.2FINANCIAL OVERVIEW ……………………………………………………………………………….. 91
5.12.3PRODUCTS OFFERED …………………………………………………………………………………. 92
5.12.4KEY DEVELOPMENTS ………………………………………………………………………………… 92
5.12.5SWOT ANALYSIS ………………………………………………………………………………………. 92
5.12.6KEY STRATEGIES………………………………………………………………………………………. 93
5.13 GENEAID BIOTECH LTD. …………………………………………………………………………………………….. 94
5.13.1COMPANY OVERVIEW ………………………………………………………………………………… 94
5.13.2FINANCIAL OVERVIEW ……………………………………………………………………………….. 94
5.13.3PRODUCTS OFFERED …………………………………………………………………………………. 95
5.13.4KEY DEVELOPMENTS ………………………………………………………………………………… 95
5.13.5SWOT ANALYSIS ………………………………………………………………………………………. 96
5.13.6KEY STRATEGIES………………………………………………………………………………………. 97
5.14 TIANGEN BIOTECH(BEIJING)CO., LTD.98
5.14.1COMPANY OVERVIEW ………………………………………………………………………………… 98
5.14.2FINANCIAL OVERVIEW ……………………………………………………………………………….. 98
5.14.3PRODUCTS OFFERED …………………………………………………………………………………. 99
5.14.4KEY DEVELOPMENTS ………………………………………………………………………………… 99
5.14.5SWOT ANALYSIS ………………………………………………………………………………………. 100
5.14.6KEY STRATEGIES………………………………………………………………………………………. 100
5.15 WUXI NEST BIOTECHNOLOGY CO., LTD ………………………………………………………………………… 101
5.15.1COMPANY OVERVIEW ………………………………………………………………………………… 101
5.15.2FINANCIAL OVERVIEW ……………………………………………………………………………….. 101
5.15.3PRODUCTS OFFERED …………………………………………………………………………………. 102
5.15.4KEY DEVELOPMENTS ………………………………………………………………………………… 102
5.15.5SWOT ANALYSIS ………………………………………………………………………………………. 103
5.15.6KEY STRATEGIES………………………………………………………………………………………. 103

LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS 15
TABLE 2 PRODUCT LAUNCH/PRODUCT DEVELOPMENT 47
TABLE 3 PARTNERSHIP/COLLABORATION 48
TABLE 4 SALES, OPERATING INCOME, R & D EXPENDITURE 2022 49
TABLE 5 QIAGEN N.V.: PRODUCTS OFFERED 52
TABLE 6 QIAGEN N. V.: KEY DEVELOPMENTS 53
TABLE 7 BIONEER CORPORATION: PRODUCTS OFFERED 56
TABLE 8 BIONEER CORPORATION: KEY DEVELOPMENTS 57
TABLE 9 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED 60
TABLE 10 T2 BIOSYSTEMS, INC.: KEY DEVELOPMENTS 60
TABLE 11 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 64
TABLE 12 HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 68
TABLE 13 CREATIVE BIOGENE: PRODUCTS OFFERED 71
TABLE 14 MAGGENOME TECHNOLOGIES PVT. LTD.: PRODUCTS OFFERED 74
TABLE 15 MAGGENOME TECHNOLOGIES PVT. LTD.: KEY DEVELOPMENTS 75
TABLE 16 DAAN GENE CO., LTD: PRODUCTS OFFERED 78
TABLE 17 MAGBIO GENOMICS INC.: PRODUCTS OFFERED 81
TABLE 18 BECKMAN COULTER INC. (DANAHER CORPORATION): PRODUCTS OFFERED 85
TABLE 19 BECKMAN COULTER INC. (DANAHER CORPORATION): KEY DEVELOPMENTS 85
TABLE 20 XI’AN TIANLONG SCIENCE AND TECHNOLOGY CO., LTD: PRODUCTS OFFERED 88
TABLE 21 GUANGZHOU DONGSHENG BIOTECH CO., LTD: PRODUCTS OFFERED 92
TABLE 22 GENEAID BOITECH LTD.: PRODUCTS OFFERED 95
TABLE 23 GENEAID BOITECH LTD.: KEY DEVELOPMENTS 95
TABLE 24 TIANGEN BIOTECH (BEIJING) CO., LTD.: PRODUCTS OFFERED 99
TABLE 25 WUXI NEST BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED 102

LIST OF FIGURES
FIGURE 1 MAGNETIC NANOPARTICLES MARKET: MARKET STRUCTURE 14
FIGURE 2 MARKET DYNAMICS: US AND CHINA MAGNETIC NANOPARTICLES MARKET 16
FIGURE 3 MARKET SIZE OF BIOMEDICAL INDUSTRY IN CHINA FROM 2015 TO 2019 (BILLION YUAN) 18
FIGURE 4 USE OF MNPS FOR BIOMEDICAL APPLICATIONS 19
FIGURE 5 SCHEMATIC PROCEDURE FOR NUCLEIC ACID PURIFICATION BY MEANS OF MAGNETIC NANOPARTICLE (MNPS) 21
FIGURE 6 DRIVERS: IMPACT ANALYSIS 22
FIGURE 7 PRICES FOR IRON ORE MARKET IN CHINA, 2019-2022, USD PER TONS 23
FIGURE 8 PRICES FOR IRON ORE MARKET IN US, 2019-2022, USD PER TONS 25
FIGURE 9 RESTRAINT: IMPACT ANALYSIS 27
FIGURE 10 RESTRAINT: IMPACT ANALYSIS 28
FIGURE 11 NANODIAGNOSTIC TECHNOLOGIES FOR SEPSIS USING MAGNETIC NANOPARTICLES (MNPS) 31
FIGURE 12 FIGURE A) REPRESENTS SCHEMATIC REPRESENTATION OF T2MR DIAGNOSTIC PLATFORM 32
FIGURE 13 FIGURE B) REPRESENTS NANOMAGNETO-DNA ASSAY FOR THE DETECTION OF BACTERIAL 16S RRNA 33
FIGURE 14 FIGURE C) REPRESENTS SERS SUBSTRATES TO ANCHOR ANTIBODY-DECORATED 34
FIGURE 15 MARKET SHARE ANALYSIS, 2022 43
FIGURE 16 COMPETITIVE BENCHMARKING 44
FIGURE 17 COMPETITIVE BENCHMARKING 45
FIGURE 18 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN MAGNETIC NANOPARTICLES MARKET (BIO-DIAGNOSTIC COMPANIES) 46
FIGURE 19 QIAGEN N. V.: FINANCIAL OVERVIEW SNAPSHOT 51
FIGURE 22 T2 BIOSYSTEMS, INC.: FINANCIAL OVERVIEW SNAPSHOT 59
FIGURE 24 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 63
FIGURE 26 HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 67
FIGURE 29 MAGGENOME TECHNOLOGIES PVT. LTD.: SWOT ANALYSIS 75
FIGURE 30 DAAN GENE CO., LTD: SWOT ANALYSIS 79
FIGURE 32 BECKMAN COULTER INC. (DANAHER CORPORATION): FINANCIAL OVERVIEW SNAPSHOT 84
FIGURE 33 BECKMAN COULTER INC. (DANAHER CORPORATION): SWOT ANALYSIS 86